Get started
Author

Federica Giugliano

Observed names: F. Giugliano, Federica Giugliano,, Giugliano, F., Giugliano, Federica
Observed institutions: Inserm, University of Milan, University of Campania "Luigi Vanvitelli", Université Paris-Saclay, Institut Gustave Roussy, European Institute of Oncology
ORCID: 0000-0003-3856-5528
Observed ORCID: 0000-0003-3856-5528
OpenAlex ID: A5004016231
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2022 · Eleonora Nicolò, Federica Giugliano, et al. · Cancer Treatment Reviews · 236
Evolution of low HER2 expression between early and advanced-stage breast cancer
2022 · Paolo Tarantino, Sara Gandini, et al. · European Journal of Cancer · 188
Bystander effect of antibody–drug conjugates: fact or fiction?
2022 · Federica Giugliano, Chiara Corti, et al. · Current Oncology Reports · 185
PARP Inhibitors for Breast Cancer Treatment
2024 · Stefania Morganti, Antonio Marra, et al. · JAMA Oncology · 99
Antibody–Drug Conjugates for the Treatment of Breast Cancer
2021 · Chiara Corti, Federica Giugliano, et al. · Cancers · 70
PDF
Pregnancy After Breast Cancer in Young BRCA Carriers
2023 · Matteo Lambertini, Eva Blondeaux, et al. · JAMA · 64
PDF
HER2-Low Breast Cancer: a New Subtype?
2023 · Chiara Corti, Federica Giugliano, et al. · Current Treatment Options in Oncology · 61
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
2021 · Gabriele Antonarelli, Federica Giugliano, et al. · Pharmaceuticals · 42
PDF
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
2021 · Federica Giugliano, Edoardo Crimini, et al. · Cancer Treatment Reviews · 38
Margetuximab for the treatment of HER2-positive metastatic breast cancer
2020 · Paolo Tarantino, Stefania Morganti, et al. · Expert Opinion on Biological Therapy · 37
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
2023 · Mariia Ivanova, Francesca Maria Porta, et al. · Genes · 35
PDF
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions
2021 · Matteo Repetto, Edoardo Crimini, et al. · Expert Review of Clinical Pharmacology · 25
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review
2021 · D. Trapani, F. Giugliano, et al. · Breast Cancer Research and Treatment · 24
PDF
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies
2025 · Federica Giugliano, Carmine De Angelis, et al. · Cancer Treatment Reviews · 21
PDF
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
2023 · Federica Giugliano, Ambra Carnevale Schianca, et al. · Cancers · 20
PDF
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 · Federica Giugliano, Elisa Giordano, et al. · Cancer Treatment Reviews · 17
Emerging treatment landscape of non-muscle invasive bladder cancer
2022 · Carmine Valenza, Gabriele Antonarelli, et al. · Expert Opinion on Biological Therapy · 15
Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19
2020 · Laura Pala, Fabio Conforti, et al. · Seminars in Oncology · 15
Neuroendocrine Immunophenotype as Predictor of Clinical Recurrence in 110 Patients with Prostate Cancer
2007 · R. Autorino, M.G. Lamendola, et al. · International Journal of Immunopathology and Pharmacology · 12
PDF
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases
2023 · Pamela Trillo, Josè Sandoval, et al. · European Journal of Cancer · 11
Harmonizing PD-L1 testing in metastatic triple negative breast cancer
2021 · Federica Giugliano, Gabriele Antonarelli, et al. · Expert Opinion on Biological Therapy · 11
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 · Eleonora Nicolò, Paolo Tarantino, et al. · The Oncologist · 9
PDF
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
2024 · Eleonora Nicolò, Sara Gandini, et al. · European Journal of Cancer · 7
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
2023 · Stefania Morganti, Antonio Marra, et al. · European Journal of Cancer · 7
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2023 · Luca Mazzarella, Federica Giugliano, et al. · The Oncologist · 7
PDF
Works count: 52
Citation count: 1,300
H-index: 16
I10-index: 21
Year
Topic
Type